XML 40 R31.htm IDEA: XBRL DOCUMENT v3.5.0.2

Purchase of LAT Pharma (Details 2)	Sep. 30, 2016 USD ($)
Business Combinations [Abstract]
Intangible assets subject to amortization	$ 2,293,770
Amortization expense in current quarter	57,344
Accumulated amortization at quarter end	$ 108,380

X

- References

No definition available.

+ Details

Name:	bivi_AccumulatedAmortization
Namespace Prefix:	bivi_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- References

No definition available.

+ Details

Name:	bivi_AmortizationExpense
Namespace Prefix:	bivi_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- References

No definition available.

+ Details

Name:	us-gaap_BusinessCombinationsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of intangible assets subject to amortization at the balance sheet date before fresh-start adjustments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=34712771&loc=d3e56426-112766

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6918054&loc=SL2890621-112765

+ Details

Name:	us-gaap_PreconfirmationAmortizableIntangibleAssetsNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant